Loading...
NASDAQ: VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
●S&P 500 since 2013
Market Cap
$114.70B
52w High
$515.67
52w Low
$362.50
P/E
29.00
Volume
1.37M
Outstanding Shares
254.00M
Company profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
CEOReshma Kewalramani
SectorHealthcare
IndustryBiotechnology
Employees6,100
IPO dateJul 24, 1991
Valuation
Forward P/E—
EV/EBITDA23.09
Enterprise value$114.72B
Stock splits
Aug 24, 20002:1
Profitability & growth
Revenue growth10.82%
Gross margin86.28%▼1.25%vs FY2024
Operating margin35.45%▲1965.58%vs FY2024
ROE21.18%▲748.87%vs FY2024
Analyst consensus
RatingBuy
Target price$549.73▲21.73%
45
Buy
10
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 4, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$4.52
$4.29
Q3FY25
ActualEst.
$4.80
$4.57
Q4FY25
ActualEst.
$5.03
$5.11
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.96B
$2.91B
Q3FY25
ActualEst.
$3.08B
$3.06B
Q4FY25
ActualEst.
$3.23B
$3.18B
Q1FY26
Next Est.
—